

Intrexon Corp

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 05-Aug-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Subsidiary Companies..... 8

Product Portfolio Summary..... 8

Product Portfolio Drugs..... 14

[Return to Table of Contents](#)

Intrexon Corp

COMPANY OVERVIEW

| | |
|---------------------------------------|---|
| Company Name | Intrexon Corp |
| Parent Company Name | Intrexon Corp |
| Website | http://www.dna.com/ |
| Country | US |
| Number of Drugs in Active Development | 14 |
| Number of Inactive Drugs | 8 |
| Number of Patents as Owner | 36 |
| Number of Patents as Third Party | 8 |
| Number of Deals | 42 |
| Key Indications | Cancer,Melioidosis,Autoimmune disease,Diabetes mellitus,Alzheimers disease,Rheumatoid arthritis,Infectious disease,Lung disease,Melanoma,Peripheral vascular disease |
| Key Target-based Actions | IL-12 agonist,Alpha 1 antitrypsin stimulator,DDC gene stimulator,IL-12 antagonist,SMN1 gene modulator,TLR4 gene inhibitor,Ecdysone receptor modulator,ATP2A2 gene stimulator,Adiponectin receptor agonist,B-lymphocyte cell adhesion molecule stimulator,Beta defensin stimulator,Beta-galactosidase modulator,Bradykinin B2 receptor antagonist,C-type lectin domain protein 12A stimulator,CD29 modulator,CD34 modulator,CD45 modulator,CD73 modulator,CFTR stimulator,Casein modulator,Cyclooxygenase stimulator,Dipeptidyl peptidase IV inhibitor,Elongation factor 2 inhibitor,Endoglin modulator,ErbB2 tyrosine kinase receptor inhibitor,Erythropoietin ligand,Glucagon-like peptide 1 agonist,Glucagon-like peptide 2 agonist,Hyaluronic acid receptor modulator,IL agonist,IL-10 agonist,IL-2 receptor alpha subunit stimulator,Interferon agonist,Interferon beta ligand,Interleukin-2 ligand,Kallikrein inhibitor,Leptin agonist,Leukocyte antigen MIC3 modulator,Mesothelin stimulator,Monocyte differentiation antigen CD14 modulator,Myelin basic protein stimulator,Nestin modulator,Neural cell adhesion molecule stimulator,Nuclear factor kappa B stimulator,Plasma protease C1 inhibitor inhibitor,RANTES ligand,Sarco endoplasmic calcium ATPase 2 modulator,Selectin modulator,Signal transducer CD24 stimulator,TNF alpha ligand,TNF gene modulator,Thy 1 membrane glycoprotein modulator,Trophoblast glycoprotein stimulator,Vitamin D3 receptor |
| Key Technologies | Biological therapeutic,Parenteral formulation unspecified,Monoclonal antibody human,Nanoparticle formulation,Cell therapy,Protein recombinant,Autologous stem cell therapy,Intravenous formulation,Mesenchymal stem cell therapy,Peptide |

COMPANY PROFILE

SUMMARY

Intrexon Corp (formerly Genomatix) is a privately-held life science company which researches and develops DNA control systems for the delivery, targeting, activation, regulation and location of biotherapeutics. The company changed its corporate name to Intrexon in August 2005.

COMPANY LOCATION

The company has its headquarters in Blacksburg, VA, with additional R&D operations in Valley Forge, PA.

In October 2011, Intrexon launched a cell engineering unit in San Diego, CA.

In February 2011, Intrexon launched its Agricultural Biotechnology Division in Research Triangle Park, North Carolina.

In April 2010, Intrexon relocated its Protein Production Division from San Francisco, CA to Foster City, CA.

[Return to Table of Contents](#)



ACQUISITIONS AND SPIN-OFFS

In July 2014, Intrexon entered into a definitive agreement to acquire Trans Ova Genetics. Trans Ova stockholders would receive approximately \$60 million in upfront cash, \$30 million in Intrexon common stock, and deferred payments of up to \$20 million.

In December 2013, Intrexon entered into a definitive agreement to acquire Medistem, for approximately \$26 million. Medistem stockholders would receive \$0.27 in cash in exchange for each share of Medistem common stock and \$1.08 worth of Intrexon common stock, based on the 20-day volume-weighted average price of Intrexon's common stock immediately prior to closing. The acquisition was subject to Intrexon's satisfactory completion of its due diligence of Medistem and its technology, customary closing conditions and Medistem stockholder approval. In March 2014, the acquisition was completed.

In October 2012, Intrexon entered into a definitive agreement to acquire an approximately 48% interest in Aqua Bounty Technologies by purchasing 48,631,444 shares for \$6 million in cash. Following the close of the transaction, Intrexon would be required to commence a tender offer for any and all of the other outstanding shares of Aqua Bounty. In January 2013, Intrexon chose not to extend the tender offer to acquire outstanding shares in Aqua Bounty.

In October 2011, Intrexon acquired Immunologix, a company focused on the production of fully human monoclonal antibodies.

In October 2011, Intrexon announced the acquisition of GT Life Sciences, and the purchase of assets comprising the LEAP cell-processing platform from CynTellect. Terms of the transactions were not disclosed.

In April 2011, the company acquired Neugenes.

In February 2011, Intrexon acquired Agarigen a company which developed a mushroom-based expression platform for rapid, high-yield production of recombinant proteins.

In September 2009, Intrexon acquired certain assets and operations from Clinical Data's subsidiary Avalon Pharmaceutical, including a bioassay facility in Germantown, MD, for \$1.5 million in cash.

In December 2006, RheoGene and Intrexon agreed to merge. The combined company, Intrexon Corp, would be based in Blacksburg, VA, and the UPMC would have an ownership stake in the new company.

FINANCIAL

In July 2013, Intrexon filed a registration statement with the SEC for an IPO of its common stock. In August 2013, the company priced its IPO of 9,999,999 common stock shares at \$16 each. The underwriters were also granted a 30-day option to buy additional 1,499,999 common stock shares. At that time, trading of shares, under the symbol 'XON' on the New York Stock Exchange was expected to begin on August 8, 2013; later that month, the IPO was closed and a total of 11,499,998 common stock shares were issued, including the complete exercise of the underwriter's over-allotment option. By September 2013, the company raised a total net proceeds of approximately \$168.3 million by the closing of the offering including the complete exercise of the underwriter's over-allotment option.

In May 2013, the company raised \$150 million from a series F preferred investment round.

In May 2011, Intrexon raised \$100 million from a series E preferred financing round.

In May 2008, Intrexon raised \$25 million from a series C-2 financing. In June 2009, the company raised an additional \$10 million from the series C-2 financing round.

In May 2007, Intrexon raised \$25 million from a series C financing round.

SUBSIDIARY COMPANIES

| Names |
|---------------|
| RheoGene Inc |
| Neugenes Corp |
| Medistem Inc |
| Immunologix |
| Agarigen Inc |


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



[Return to Table of Contents](#)

Drugs by Indication Table


| Indication | Active | Inactive | Total |
|--------------------------|--------|----------|-------|
| Neoplasm | 6 | 2 | 8 |
| Infectious disease | 3 | 4 | 7 |
| Respiratory disease | 2 | 3 | 5 |
| Neurological disease | 3 | 1 | 4 |
| Immune disorder | 2 | 0 | 2 |
| Gastrointestinal disease | 2 | 0 | 2 |
| Endocrine disease | 2 | 0 | 2 |
| Dermatological disease | 2 | 0 | 2 |
| Metabolic disorder | 2 | 0 | 2 |
| Genitourinary disease | 1 | 1 | 2 |
| Cardiovascular disease | 1 | 0 | 1 |
| Andrology | 0 | 1 | 1 |
| Growth disorder | 1 | 0 | 1 |
| Injury | 0 | 1 | 1 |
| Degeneration | 1 | 0 | 1 |
| Inflammatory disease | 1 | 0 | 1 |
| Musculoskeletal disease | 1 | 0 | 1 |

[Return to Table of Contents](#)



Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status | Number of Drugs |
|-------------------------|-----------------|
| Phase 2 Clinical | 2 |
| Phase 1 Clinical | 1 |
| Discovery | 11 |
| No Development Reported | 8 |

[Return to Table of Contents](#)

DEALS

| Deal Type | Principal | | Partner | | Total |
|--|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Patent - Exclusive Rights | 2 | 0 | 1 | 0 | 3 |
| Drug - Early Research/Development | 3 | 0 | 4 | 0 | 7 |
| Drug - Development/Commercialization License | 2 | 0 | 0 | 0 | 2 |
| Technology - Delivery/Formulation | 0 | 0 | 2 | 0 | 2 |
| Technology - Target Validation | 2 | 0 | 0 | 0 | 2 |
| Drug - Funding | 2 | 0 | 0 | 0 | 2 |
| Drug - Development Services | 1 | 0 | 3 | 0 | 4 |
| Drug - Screening/Evaluation | 1 | 0 | 0 | 0 | 1 |
| Patent - Non-Exclusive Rights | 1 | 0 | 0 | 0 | 1 |
| Technology - Other Proprietary | 14 | 0 | 2 | 0 | 16 |
| Drug - Commercialization License | 1 | 0 | 0 | 0 | 1 |

CLINICAL TRIALS

Trials by Condition Studied

| Condition Studied | Ongoing | All |
|------------------------|---------|-----|
| Cardiovascular disease | 0 | 2 |
| Neoplasm | 0 | 1 |

Trials by Phase

| Phase | Ongoing | All |
|---------|---------|-----|
| Phase 2 | 0 | 1 |
| Phase 1 | 0 | 2 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

PATENTS *

| Indication | As Owner | As Third Party | Total |
|---------------------------|----------|----------------|-------|
| Cardiovascular disease | 16 | 3 | 19 |
| Endocrine disease | 7 | 2 | 9 |
| Gastrointestinal disease | 7 | 2 | 9 |
| Genitourinary disease | 5 | 0 | 5 |
| Growth disorder | 0 | 1 | 1 |
| Hematological disease | 2 | 1 | 3 |
| Degeneration | 2 | 3 | 5 |
| Andrology | 2 | 0 | 2 |
| Immune disorder | 10 | 3 | 13 |
| Psychiatric disorder | 2 | 0 | 2 |
| Musculoskeletal disease | 5 | 2 | 7 |
| Neoplasm | 18 | 3 | 21 |
| Ocular disease | 2 | 0 | 2 |
| Genetic disorder | 5 | 0 | 5 |
| Metabolic disorder | 8 | 2 | 10 |
| Neurological disease | 11 | 3 | 14 |
| Nutritional disorder | 1 | 0 | 1 |
| Respiratory disease | 7 | 1 | 8 |
| Infectious disease | 5 | 0 | 5 |
| Injury | 4 | 0 | 4 |
| Toxicity and intoxication | 1 | 0 | 1 |
| Unidentified indication | 3 | 0 | 3 |
| Inflammatory disease | 8 | 1 | 9 |
| Gynecology and obstetrics | 1 | 0 | 1 |
| Dermatological disease | 6 | 2 | 8 |

[Return to Table of Contents](#)



| | | | |
|--------------------|---|---|---|
| Surgical procedure | 2 | 0 | 2 |
|--------------------|---|---|---|

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

ERC-124

| | |
|-----------------------------|--|
| Drug Name | ERC-124 |
| Key Synonyms | |
| Originator Company | Medistem Inc |
| Active Companies | ERCell LLC, Medistem Inc |
| Inactive Companies | |
| Highest Status | Phase 2 Clinical |
| Active Indications | Renal failure, Cardiac failure, Neurodegenerative disease, Peripheral vascular disease, Lung disease |
| Target-based Actions | |
| Other Actions | Interferon gamma receptor antagonist, Angiogenesis stimulator, Hypoglycemic agent, Cardioprotectant, IL-4 release stimulator |
| Technologies | Intravenous formulation, Intramuscular formulation, Biological therapeutic, Allogenic stem cell therapy, Mesenchymal stem cell therapy |
| Last Change Date | 10-Mar-2014 |

Ad-RTS-IL-12

| | |
|-----------------------------|---|
| Drug Name | Ad-RTS-IL-12 |
| Key Synonyms | |
| Originator Company | ZIOPHARM Oncology Inc |
| Active Companies | ZIOPHARM Oncology Inc, Intrexon Corp |
| Inactive Companies | |
| Highest Status | Phase 2 Clinical |
| Active Indications | Stage IV melanoma, Stage III melanoma, Glioblastoma, Metastatic breast cancer |
| Target-based Actions | IL-12 agonist |
| Other Actions | Immunostimulant, Adenovirus based gene therapy, Anticancer |
| Technologies | Intratumoral formulation, Oral formulation, Virus recombinant, Biological therapeutic |
| Last Change Date | 23-Jul-2014 |

[Return to Table of Contents](#)

SGX-94

| | |
|-----------------------------|---|
| Drug Name | SGX-94 |
| Key Synonyms | |
| Originator Company | University of British Columbia |
| Active Companies | SciClone Pharmaceuticals Inc, Soligenix Inc, Intrexon Corp |
| Inactive Companies | University of British Columbia |
| Highest Status | Phase 2 Clinical |
| Active Indications | Radiation sickness, Oral mucositis, Melioidosis |
| Target-based Actions | Sequestosome 1 inhibitor |
| Other Actions | Anti-inflammatory, Antibacterial |
| Technologies | Systemic formulation unspecified, Biological therapeutic, Peptide |
| Last Change Date | 17-Jun-2014 |

DC-RTS-IL-12

| | |
|-----------------------------|--|
| Drug Name | DC-RTS-IL-12 |
| Key Synonyms | |
| Originator Company | Intrexon Corp |
| Active Companies | ZIOPHARM Oncology Inc, Intrexon Corp |
| Inactive Companies | |
| Highest Status | Phase 1 Clinical |
| Active Indications | Solid tumor |
| Target-based Actions | IL-12 agonist |
| Other Actions | Genetically engineered autologous cell therapy, Anticancer, Immunostimulant |
| Technologies | Intratumoral formulation, Cell therapy, Oral formulation, Biological therapeutic |
| Last Change Date | 18-Nov-2013 |

[Return to Table of Contents](#)

rHuA1AT (sc Enhanze, A1AT deficiency), Intrexon

| | |
|-----------------------------|---|
| Drug Name | rHuA1AT (sc Enhanze, A1AT deficiency), Intrexon |
| Key Synonyms | |
| Originator Company | Intrexon Corp |
| Active Companies | Intrexon Corp |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Respiratory disease, Diabetes mellitus |
| Target-based Actions | Alpha 1 antitrypsin stimulator |
| Other Actions | Hypoglycemic agent |
| Technologies | Subcutaneous formulation, Biological therapeutic, Protein recombinant |
| Last Change Date | 28-Mar-2012 |

ddRNAi therapy (rheumatoid arthritis), Medistem/Benitec

| | |
|-----------------------------|---|
| Drug Name | ddRNAi therapy (rheumatoid arthritis), Medistem/Benitec |
| Key Synonyms | |
| Originator Company | Medistem Inc |
| Active Companies | Medistem Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Rheumatoid arthritis |
| Target-based Actions | IL-12 antagonist |
| Other Actions | Therapeutic vaccine, shRNA agent, Anti-inflammatory, Unspecified non-viral vector based gene therapy, Genetically engineered autologous cell therapy, Immunomodulator |
| Technologies | Intravenous formulation, Biological therapeutic, Parenteral formulation unspecified, Autologous stem cell therapy |
| Last Change Date | 10-Mar-2014 |

[Return to Table of Contents](#)

pancreatic islet therapy (endometrial regenerative cells, type 1 diabetes), Medistem

| | |
|-----------------------------|---|
| Drug Name | pancreatic islet therapy (endometrial regenerative cells, type 1 diabetes), Medistem |
| Key Synonyms | |
| Originator Company | Yale University |
| Active Companies | Medistem Inc |
| Inactive Companies | Yale University |
| Highest Status | Discovery |
| Active Indications | Insulin dependent diabetes |
| Target-based Actions | |
| Other Actions | Hypoglycemic agent |
| Technologies | Biological therapeutic, Parenteral formulation unspecified, Allogenic stem cell therapy |
| Last Change Date | 11-Mar-2014 |

antibody drug conjugates (cancer), Intrexon

| | |
|-----------------------------|---|
| Drug Name | antibody drug conjugates (cancer), Intrexon |
| Key Synonyms | |
| Originator Company | Intrexon Corp |
| Active Companies | Intrexon Corp |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Cancer |
| Target-based Actions | |
| Other Actions | Anticancer |
| Technologies | Antibody conjugated, Biological therapeutic |
| Last Change Date | 28-Mar-2012 |

[Return to Table of Contents](#)

fully human monoclonal antibodies (cancer/infection/autoimmune disease), Intrexon

| | |
|-----------------------------|---|
| Drug Name | fully human monoclonal antibodies (cancer/infection/autoimmune disease), Intrexon |
| Key Synonyms | |
| Originator Company | Immunologix |
| Active Companies | Intrexon Corp |
| Inactive Companies | Immunologix |
| Highest Status | Discovery |
| Active Indications | Cancer, Infectious disease, Autoimmune disease |
| Target-based Actions | |
| Other Actions | Antimicrobial, Anticancer monoclonal antibody, Immunomodulator |
| Technologies | Monoclonal antibody human, Biological therapeutic, Parenteral formulation unspecified |
| Last Change Date | 15-Jun-2012 |

fully human mAbs (Alzheimers disease), Intrexon

| | |
|-----------------------------|---|
| Drug Name | fully human mAbs (Alzheimers disease), Intrexon |
| Key Synonyms | |
| Originator Company | Immunologix |
| Active Companies | Intrexon Corp |
| Inactive Companies | Immunologix |
| Highest Status | Discovery |
| Active Indications | Alzheimers disease |
| Target-based Actions | |
| Other Actions | Neuroprotectant |
| Technologies | Monoclonal antibody human, Biological therapeutic, Parenteral formulation unspecified |
| Last Change Date | 12-Jun-2012 |

[Return to Table of Contents](#)

interferon-alpha plasmid transgene therapy (melanoma), ZIOPHARM/Intrexon

| | |
|-----------------------------|--|
| Drug Name | interferon-alpha plasmid transgene therapy (melanoma), ZIOPHARM/Intrexon |
| Key Synonyms | |
| Originator Company | ZIOPHARM Oncology Inc |
| Active Companies | Intrexon Corp, ZIOPHARM Oncology Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Melanoma |
| Target-based Actions | IFNA gene modulator |
| Other Actions | Anticancer, Plasmid based gene therapy, Immunostimulant |
| Technologies | DNA technology, Intramuscular formulation, Biological therapeutic |
| Last Change Date | 19-Mar-2013 |

SMN1-based gene replacement stem cell therapy (spinal muscular atrophy), Intrexon

| | |
|-----------------------------|--|
| Drug Name | SMN1-based gene replacement stem cell therapy (spinal muscular atrophy), Intrexon |
| Key Synonyms | |
| Originator Company | Intrexon Corp |
| Active Companies | Intrexon Corp |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Spinal muscular atrophy |
| Target-based Actions | SMN1 gene modulator |
| Other Actions | Stem cell modulator |
| Technologies | Biological therapeutic, Parenteral formulation unspecified, Autologous stem cell therapy |
| Last Change Date | 29-May-2014 |

[Return to Table of Contents](#)



SGX-101

| | |
|-----------------------------|---|
| Drug Name | SGX-101 |
| Key Synonyms | |
| Originator Company | Soligenix Inc |
| Active Companies | Soligenix Inc, Intrexon Corp |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Melioidosis |
| Target-based Actions | |
| Other Actions | Antibacterial, Unspecified drug target |
| Technologies | Monoclonal antibody human, Biological therapeutic, Parenteral formulation unspecified |
| Last Change Date | 18-Oct-2013 |

transgene enabled cell-based therapeutics (Mesenchymal Lineage Cells/ RheoSwitch, cancer), ZIOPHARM Oncology/ Mesoblast/ Intrexon

| | |
|-----------------------------|---|
| Drug Name | transgene enabled cell-based therapeutics (Mesenchymal Lineage Cells/ RheoSwitch, cancer), ZIOPHARM Oncology/ Mesoblast/ Intrexon |
| Key Synonyms | |
| Originator Company | ZIOPHARM Oncology Inc |
| Active Companies | Mesoblast Ltd, ZIOPHARM Oncology Inc, Intrexon Corp |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Cancer |
| Target-based Actions | |
| Other Actions | Gene therapy, Anticancer |
| Technologies | Biological therapeutic, Mesenchymal stem cell therapy |
| Last Change Date | 19-Feb-2014 |

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)